ArticleNPJ vaccines2018
A recombinant conjugated pneumococcal vaccine that protects against murine infections with a similar efficacy to Prevnar-13.
Article in NPJ vaccines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 62 citations in OpenAlex.
- High-throughput antigen discovery using Functional Genomic Vaccinology (FGV) identifies protective Streptococcus pneumoniae vaccine candidates.Nature communications · 2026Article
- Development and evaluation of a dual-target glycoconjugate againstFrontiers in immunology · 2026Article
- Characterizing and engineering post-translational modifications with high-throughput cell-free expression.Nature communications · 2025Article
- Rhamnose polysaccharide-decorated outer membrane vesicles as a vaccine candidate targeting Group A Streptococcus fromVaccine: X · 2025Article
- Recent Advances in Bioconjugate Vaccine Development.Vaccines · 2025Review
- Recombinant production platform for Group A Streptococcus glycoconjugate vaccines.NPJ vaccines · 2025Article
- Essential role of proline synthesis and the one-carbon metabolism pathways for systemic virulence ofmBio · 2024Article
- Recurrent community-acquired pneumococcal meningitis in adults with and without identified predisposing factors.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Bacterial surface lipoproteins mediate epithelial microinvasion byInfection and immunity · 2024Article
- Efficient Production of Self-Assembled Bioconjugate Nanovaccines againstNanomaterials (Basel, Switzerland) · 2024Article
- Engineering Escherichia coli for increased Und-P availability leads to material improvements in glycan expression technology.Microbial cell factories · 2024Article
- Analysis of immunogenicity and purification methods in conjugated polysaccharide vaccines: a new approach in fighting pathogenic bacteria.Frontiers in immunology · 2024Review
- Recent advances in the biosynthesis of polysaccharide-based antimicrobial glycoconjugate vaccines.Frontiers in microbiology · 2024Review
- Semisynthetic Pneumococcal Glycoconjugate Nanovaccine.Bioconjugate chemistry · 2023Article
- Progress towards a glycoconjugate vaccine against Group A Streptococcus.NPJ vaccines · 2023Review
- A combinatorial DNA assembly approach to biosynthesis of N-linked glycans in E. coli.Glycobiology · 2023Article
- Review
- Conjugation Mechanism for Pneumococcal Glycoconjugate Vaccines: Classic and Emerging Methods.Bioengineering (Basel, Switzerland) · 2022Review
- The remarkable history of pneumococcal vaccination: an ongoing challenge.Pneumonia (Nathan Qld.) · 2022Review
- Engineering a suite of E. coli strains for enhanced expression of bacterial polysaccharides and glycoconjugate vaccines.Microbial cell factories · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
The pneumococcal conjugate vaccine (PCV) strongly protects against vaccine serotypes, but the rapid expansion of non-vaccine serotype disease and the vaccine's high expense has reduced its overall impact. We have developed Protein Glycan Coupling Technology (PGCT) as a flexible methodology for making low-cost polysaccharide/protein glycoconjugates recombinantly in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.